ReviewThe Journal of allergy and clinical immunology2012
Novel targeted therapies for eosinophilic disorders.
Review in The Journal of allergy and clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Genome-wide analysis highlights contribution of immune system pathways to the genetic architecture of asthma.Nature communications · 2020Pooled it
- Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab.International journal of clinical pharmacology and therapeutics · 2015Trial
- A pilot study of omalizumab in eosinophilic esophagitis.PloS one · 2015Trial
- The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders.The Journal of allergy and clinical immunology · 2014Trial
- Immunotherapy as rescue for cardiomyopathy in Omenn syndrome.Journal of human immunity · 2025Article
- Article
- HES and EGPA: Two Sides of the Same Coin.Mayo Clinic proceedings · 2023Review
- Pediatric hypereosinophilic syndrome associated with liver damage, portal vein, splenic vein and superior mesenteric vein thromboses: a case report.BMC pediatrics · 2023Article
- Sweet taste receptor agonists attenuate macrophage IL-1β expression and eosinophilic inflammation linked to autophagy deficiency in myeloid cells.Clinical and translational medicine · 2022Article
- Recent advances of eosinophils and its correlated diseases.Frontiers in public health · 2022Review
- Ginsenoside F1 Attenuates Eosinophilic Inflammation in Chronic Rhinosinusitis by Promoting NK Cell Function.Journal of ginseng research · 2021Article
- Eosinophilic Gastritis/Gastroenteritis.Current gastroenterology reports · 2021Review
- CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation.Mucosal immunology · 2021Article
- Idiopathic hypereosinophilic syndrome with formation of multiple liver mass lesions.Clinical journal of gastroenterology · 2020Article
- Sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating βThe Journal of allergy and clinical immunology · 2018Article
- Glycobiology of Eosinophilic Inflammation: Contributions of Siglecs, Glycans, and Other Glycan-Binding Proteins.Frontiers in medicine · 2017Review
- Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: A case report and literature review.Medicine · 2016Review
- "Siglec"ting the allergic response for therapeutic targeting.Glycobiology · 2016Review
- Biological Modulators in Eosinophilic Diseases.Clinical reviews in allergy & immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 13 institutions in 6 countries.
Funding
Abstract
Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.